Literature DB >> 3920779

Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction.

J J Hoffmann, F J Van Rey, J J Bonnier.   

Abstract

The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems were studied in 13 patients treated for acute myocardial infarction with a short intravenous infusion of 30 mg of the new drug. In 12/13 patients (92%) significant changes were observed in the concentrations of fibrinogen, fibrin(ogen) degradation products, plasminogen, alpha 2-antiplasmin and F VIII:C; all changes indicating a substantial degree of systemic fibrinolysis. In only one patient were no signs of systemic activation of the fibrinolytic system observed. The therapeutic efficacy of the drug was 85% in this study.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920779     DOI: 10.1016/0049-3848(85)90089-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

Authors:  J P Monassier; M Hanssen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?

Authors:  W Kasper; T Meinertz; H Just
Journal:  Klin Wochenschr       Date:  1986-04-01

3.  Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.

Authors:  V J Marder; R L Rothbard; P G Fitzpatrick; C W Francis; E C Norry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.

Authors:  L Kaspar; R Karnik; E Sehnal; P Zajicek; B Ziegler; J Slany
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.

Authors:  J J Hoffmann; J J Bonnier; J B de Swart; P Custers; M Vijgen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.

Authors:  M L Brochier; L Quilliet; H Kulbertus; P Materne; B Letac; A Cribier; J P Monassier; A Sacrez; J P Favier
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  M Samama; J Conard; E Verdy; P van Dreden; G Nguyen; A Combrisson; J Acar
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.

Authors:  J Renkin; C C Beys; E Lavenne-Pardonge; H Pintens; J Col
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 9.  Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.

Authors:  J P Monk; R C Heel
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.